Pharmacovigilance is much more than collecting and reporting adverse events. It is a complex, interconnected system designed to continuously monitor the safety of medicinal products, identify emerging risks and ensure that new safety information is translated into appropriate action.
The European Medicines Agency’s Good Pharmacovigilance Practices (GVP) recognize that some activities are particularly important because a failure in these areas could directly affect patient safety, public health or regulatory compliance. GVP Module I therefore identifies a number of critical pharmacovigilance processes that require robust procedures, appropriate resources, effective oversight and reliable business continuity arrangements. (European Medicines Agency (EMA))
For Marketing Authorization Holders (MAHs), ensuring that all these processes operate effectively can be challenging. This is particularly true for organizations managing multiple products, countries, partners and service providers. Working with an experienced pharmacovigilance provider can therefore become an important element of a resilient and compliant PV system.
What are the critical pharmacovigilance processes?
Critical PV processes cover virtually the entire safety lifecycle of a medicinal product.
They include continuous monitoring of the safety profile and benefit-risk balance of authorized products, implementation and assessment of risk management systems, and evaluation of the effectiveness of risk-minimization measures.
Another particularly important area is ICSR management. The complete lifecycle of an Individual Case Safety Report—from collection and follow-up through coding, duplicate detection, medical evaluation, quality control and electronic transmission—needs to operate within strict regulatory timelines.
Other critical activities include signal management; preparation, quality control and submission of periodic safety reports; responding to competent-authority requests and commitments; interactions between pharmacovigilance and product-quality systems; communication of safety concerns; maintaining product information in line with current scientific knowledge; and implementation of safety-related variations with the necessary urgency.
Together, these activities form a highly interconnected system. A problem in one process can rapidly affect others. A delay in case processing, for example, may influence signal detection, aggregate reporting, regulatory compliance and ultimately the organization’s understanding of the benefit-risk profile of a product.
This is why the objective of the pharmacovigilance quality system is not simply to perform individual tasks correctly. GVP describes a broader quality cycle encompassing planning, adherence, quality control and assurance, and continuous improvement. (European Medicines Agency (EMA))
Business continuity is itself a critical requirement
Pharmacovigilance cannot simply stop because a database becomes unavailable, an office cannot be accessed or key personnel are temporarily unavailable.
GVP therefore requires organizations to establish business continuity arrangements on a risk-based basis, addressing events that could seriously affect staff, infrastructure or PV processes and providing alternative mechanisms for the urgent exchange of safety information.
This requirement is particularly relevant for time-critical activities such as expedited safety reporting. EMA specifically emphasizes the need for adequate business-continuity and backup systems to maintain regulatory reporting in the event of technical failures. (European Medicines Agency (EMA))
A mature pharmacovigilance organization must consequently ask not only “Is this process compliant today?”, but also “Will it continue to operate effectively tomorrow if something unexpected happens?”
Why an experienced pharmacovigilance service provider makes a difference
The increasing complexity of pharmacovigilance means that maintaining expertise internally across every PV discipline can require considerable resources.
An experienced provider can add value because it sees the PV system as a whole rather than as a collection of isolated activities. Case management, signal detection, aggregate reporting, risk management, quality management, regulatory intelligence and safety communication are strongly interdependent.
A specialized partner can also provide operational capacity when volumes fluctuate, access to specialist expertise when complex situations arise, and additional resilience when critical activities require backup resources.
Most importantly, an experienced service provider understands that outsourcing a pharmacovigilance activity does not mean outsourcing responsibility. EMA guidance makes clear that MAHs may subcontract PV activities, but retain ultimate responsibility for their pharmacovigilance system. Appropriate written agreements, clear roles and responsibilities, appropriate oversight and suitable governance therefore remain essential. (European Medicines Agency (EMA))
The right outsourcing model is consequently not simply about transferring workload. It is about creating an operating model in which quality, compliance, expertise, oversight and continuity remain aligned.
PVpharm: supporting critical PV processes through expertise and governance
PVpharm is positioned as a specialized pharmacovigilance service provider, with its service portfolio encompassing Pharmacovigilance Services, Audit Services, Clinical Safety, Medical Services, Quality Management and Training Services.
This multidisciplinary approach is particularly important when supporting critical PV processes because many compliance risks arise precisely at the interfaces between activities.
Effective outsourcing therefore requires more than qualified individuals performing individual tasks. It requires governance, coordination and clearly defined accountability. PVpharm’s own operating approach places emphasis on qualified partners, accountable leadership and governance designed to keep quality, speed and compliance aligned.
Whether supporting an individual pharmacovigilance process or a broader outsourced PV operating model, an experienced provider can help organizations establish scalable processes, maintain appropriate oversight, identify emerging compliance risks and ensure that critical activities continue to operate reliably.
From regulatory compliance to patient protection
The concept of “critical processes” is ultimately about much more than inspection readiness.
The overall objectives of the pharmacovigilance system include complying with legal requirements, preventing harm from adverse reactions, promoting the safe and effective use of medicines and contributing to the protection of patients and public health. (European Medicines Agency (EMA))
That makes the reliability of critical PV processes fundamental.
Strong procedures, validated systems and documented responsibilities are necessary. But experienced people, effective oversight and a resilient operating model are what make those elements work together in practice.
For pharmaceutical companies facing increasing operational complexity, a specialized pharmacovigilance partner such as PVpharm can provide the experience, capacity and governance needed to support these processes—not simply to meet regulatory requirements, but to build a pharmacovigilance system capable of protecting patients consistently, even when circumstances change.
Because in pharmacovigilance, critical processes cannot afford to fail.
Please contact us for more information.
